ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lisdexamfetamine

Also written as “SPD489”, “NRP104” and “SPD489 (Lisdexamfetamine dimesylate)”.

Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Schizophrenia · Depressive Disorder, Major · Binge-Eating Disorder · Sleep Deprivation, led by 3 companies.

Drug pageLisdexamfetamine: every studyAll 97 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 10, 200747 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda450 open or runningphase 4since Jul 10, 2007Oct 31, 2005none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jul 25, 2025Jul 25, 2025none ahead
Knoa Pharmaits history only10 open or runningphase 3since Aug 28, 2015Aug 28, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 26 studies since Oct 31, 2005.

  1. Mar 29, 2011Phase 4 study in Attention Deficit Disorder with HyperactivityNCT01328756 · 314 enrolled · Belgium, Germany, Hungary and more
  2. Sep 15, 20113 phase 3 studies in Depressive Disorder, MajorNCT01436175, NCT01436162, NCT01436149
  3. Sep 15, 2011Phase 2 study in Depressive Disorder, MajorNCT01435759 · 1,197 enrolled · United States, Argentina, Australia and more
  4. Oct 19, 2011Phase 1 study in SchizophreniaNCT01457339 · 31 enrolled · United States
  5. Mar 6, 20122 phase 4 studies in Attention Deficit Disorder with HyperactivityNCT01552915, NCT01552902
  6. Aug 1, 2012Phase 3 study in Binge-Eating DisorderNCT01657019 · 604 enrolled · United States, Germany, Spain
  7. Oct 29, 20122 phase 3 studies in Binge-Eating DisorderNCT01718509, NCT01718483
  8. Nov 28, 2012Phase 3 study in SchizophreniaNCT01738698 · 4 enrolled · United States
  9. Jan 2, 20132 phase 3 studies in SchizophreniaNCT01760993, NCT01760889
  10. Jun 27, 2013Phase 1 study in Healthy VolunteersNCT01890785 · 30 enrolled · United States
  11. Dec 6, 2013Phase 3 study in Binge-Eating DisorderNCT02009163 · 418 enrolled · United States, Canada, Germany and more
  12. Mar 19, 2015Phase 2 study in Attention Deficit Disorder with HyperactivityNCT02402166 · 24 enrolled · United States
  13. Jun 4, 2015Phase 3 study in Attention Deficit Disorder with HyperactivityNCT02466386 · 113 enrolled · United States
  14. Aug 9, 2017Phase 3 study in Attention Deficit Disorder with HyperactivityNCT03260205 · 199 enrolled · United States

TargetBeta

“Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule

Studies

All 45 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03260205Attention Deficit Disorder with Hyperactivity · United States3CompletedOct 23, 2018199
NCT02466386Attention Deficit Disorder with Hyperactivity · United States3CompletedJan 3, 2020113
NCT02402166Attention Deficit Disorder with Hyperactivity · United States2CompletedJun 30, 201624
NCT02009163Binge-Eating Disorder · United States, Canada, Germany and more3CompletedApr 8, 2015418
NCT01890785Healthy Volunteers · United States1CompletedAug 22, 201330
NCT01760993Schizophrenia · United States3TerminatedApr 1, 20132
NCT01760889Schizophrenia · United States3TerminatedApr 1, 20131
NCT01738698Schizophrenia · United States3TerminatedApr 1, 20134
NCT01718509Binge-Eating Disorder · United States, Germany3CompletedSep 20, 2013390
NCT01718483Binge-Eating Disorder · United States, Germany, Spain and more3CompletedSep 25, 2013383
NCT01657019Binge-Eating Disorder · United States, Germany, Spain3CompletedOct 21, 2014604
NCT01552915Attention Deficit Disorder with Hyperactivity · United States4CompletedJan 22, 2014464
NCT01552902Attention Deficit Disorder with Hyperactivity · United States, Canada, Germany and more4CompletedMay 22, 2014549
NCT01457339Schizophrenia · United States1CompletedJan 20, 201231
NCT01436175Depressive Disorder, Major · United States, Canada, Chile and more3TerminatedMar 27, 20141,570
NCT01436162Depressive Disorder, Major · United States, Belgium, Czechia and more3CompletedDec 10, 20131,105
NCT01436149Depressive Disorder, Major · United States, Canada, Croatia and more3CompletedDec 23, 20131,262
NCT01435759Depressive Disorder, Major · United States, Argentina, Australia and more2CompletedJan 17, 20141,197
NCT01328756Attention Deficit Disorder with Hyperactivity · Belgium, Germany, Hungary and more4CompletedSep 30, 2014314
NCT01291173Binge-Eating Disorder · United States2CompletedJan 30, 2012271
NCT01274221Attention Deficit Disorder with Hyperactivity · United States3WithdrawnMay 4, 20110
NCT01234298Negative Symptoms of Schizophrenia3WithdrawnFeb 24, 20140
NCT01106430Attention Deficit Disorder with Hyperactivity · United States, Belgium, Canada and more3CompletedJul 19, 2012267
NCT01101022ADHD Specifically With Executive Function Impairment · United States4CompletedNov 29, 2010161
NCT01096680Sleep Deprivation · United States2CompletedJul 18, 2010135
NCT01010750Attention Deficit Disorder with Hyperactivity · United States1CompletedMar 28, 201018
NCT00985725Depressive Disorder, Major · United States2CompletedApr 18, 2011143
NCT00922272Schizophrenia · United States2CompletedJan 20, 201192
NCT00919867Healthy · United States1CompletedJul 30, 200942
NCT00905424Depressive Disorder, Major · United States2CompletedAug 4, 2010246
NCT00877487Attention Deficit Disorder with Hyperactivity · United States4CompletedJul 8, 2010123
NCT00784654Attention Deficit Disorder with Hyperactivity · United States, Belgium, France and more3CompletedOct 26, 2011276
NCT00776555Healthy · United States1TerminatedMar 31, 20093
NCT00763971Attention Deficit Disorder with Hyperactivity · Belgium, France, Germany and more3CompletedMar 16, 2011336
NCT00764868Attention Deficit Disorder with Hyperactivity · United States3CompletedApr 22, 2010269
NCT00746733Healthy Volunteers · United States1CompletedOct 26, 200824
NCT00735371Attention Deficit Disorder with Hyperactivity · United States3CompletedApr 6, 2009314
NCT00557011Attention Deficit Disorder with Hyperactivity2Completed52
NCT00556296Attention Deficit Disorder with Hyperactivity3Completed297
NCT00500149Attention Deficit Disorder with Hyperactivity · United States3CompletedDec 5, 2007129
NCT00500071Attention Deficit Disorder with Hyperactivity · United States4CompletedJan 2, 2008318
NCT00337285Attention Deficit Disorder with Hyperactivity · United States3CompletedNov 2007349
NCT00334880Attention Deficit Disorder with Hyperactivity · United States3Completed420
NCT00248092Attention Deficit Disorder with Hyperactivity · United States2Completed36
NCT00247572Attention Deficit Disorder with Hyperactivity · United States2Completed12

How it is read

Names in the registry

  • “SPD489”, 6 entries
  • “NRP104”, 6 entries
  • “SPD489 (Lisdexamfetamine dimesylate)”, 5 entries
  • “Lisdexamfetamine dimesylate”, 5 entries
  • “Lisdexamfetamine Dimesylate”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.